Indication
Neurotransmitter Agents
4 clinical trials
5 products
Clinical trial
A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective DisorderStatus: Completed, Estimated PCD: 2022-09-23
Product
LY03010Clinical trial
A Study to Evaluate the PK Profiles of LY03010 and Relative Bioavailability at Steady-state of LY03010 Versus INVEGA SUSTENNA in Schizophrenia PatientsStatus: Completed, Estimated PCD: 2022-03-15
Product
Paliperidone palmitateProduct
Invega SustennaClinical trial
A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi SyndromeStatus: Recruiting, Estimated PCD: 2024-01-18
Product
GuanfacineClinical trial
An Open-Label Clinical Trial of Simultaneous Administration of Oral Aspirin and Ketamine as Adjunct to Oral Antidepressant Therapy in Treatment-Resistant DepressionStatus: Completed, Estimated PCD: 2024-05-17
Product
VTS-K